Trial Profile
A study to investigate safety and efficacy of Pazopanib in patients with metastatic renal cell carcinoma as a first line therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Dec 2015 New trial record